First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

NCT04417465 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors Cancer

Interventions

DRUG: ABBV-CLS-579
DRUG: PD-1 inhibitor
DRUG: VEGFR TKI

Sponsor

AbbVie

Collaborators

[object Object]